Abstracts tagged "Gene Expression"

Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
David Fox¹, Laura Cooney², Lia Stelzig³, Robert Lafyatis⁴, Johann Gudjonsson⁵, Lam Tsoi⁶, Maureen Mayes⁷, Ankoor Shah⁸, Suzanne Kafaja⁹, William Barry³, Ellen Goldmuntz¹⁰, Dawn Smilek¹¹ and Dinesh Khanna⁶, ¹University of Michigan, Dexter, MI, ²University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ³Rho, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, MI, ⁷UTHealth Houston Division of Rheumatology, Houston, TX, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ¹⁰Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, ¹¹Immune Tolerance Network, UCSF, San Francisco, CA
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
Abstract Number: 0083 • ACR Convergence 2024
Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice
Mariia Korshko¹, Shaghayegh Foroozan Boroojeni² and Nigil Haroon³, ¹University Health Network, Toronto, ON, Canada, ²UHN, Toronto, Canada, ³Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
Abstract Number: 0953 • ACR Convergence 2024
Establishment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension Specific Endothelial Cells Through iPSCs and Their Functional and Molecular Analyses
Yuki Kudo¹, Masaru Kato¹, Yuhei Shibata², Ryo Hisada¹, Michihito Kono¹, Yuichiro Fujieda¹, Olga Amengual³ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Rheumatology Department, Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan., Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) is of particularly clinical interest since its outcomes remain unfavorable despite modern PAH therapies. Previous reports showed…
Abstract Number: 1839 • ACR Convergence 2024
PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
Abstract Number: 0316 • ACR Convergence 2024
Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
Mayu Magi¹, Hiroto Yoshida¹, Hiroya Tamai², Kotaro Matsumoto², Keiko Yoshimoto², Yoshihiro Matsumoto¹, Tetsuhiro Soeda¹ and Yuko Kaneko², ¹Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been shown to be effective in the treatment of adult-onset Still's disease (AOSD), a systemic inflammatory disease.…
Abstract Number: 1105 • ACR Convergence 2024
PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor M. Mora-Cuesta³, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁴, José M. Cifrián⁵, Ricardo Blanco-Alonso⁶ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the main causes of mortality in patients with autoimmune diseases (ADs) [1]. The early diagnosis of AD-ILD+…
Abstract Number: 2036 • ACR Convergence 2024
CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia
Yanhong Li¹, Xiufeng Bai² and Yi Liu³, ¹West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, Sichuan, China (People's Republic), ³West China Hospital of Sichuan University, Chengdu, Sichuan, China
Background/Purpose: Progressive pseudo-rheumatoid dysplasia (PPRD) is a rare autosomal recessive disorder characterized by non-inflammatory joint issues that primarily affect the articular cartilage. This leads to…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 1132 • ACR Convergence 2024
Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy
Dylan Richards¹, Marion Vetter¹, Matthew Germinaro¹, Bram Verstockt², Raja Atreya³, Julián Panés⁴, Bruce E. Sands⁵, Brian G. Feagan⁶, Bradford McRae⁷, Daniel Cua¹, Patrick Branigan¹ and Tom C. Freeman¹, ¹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ²Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium, ³Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, Barcelona, Spain, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY, ⁶Alimentiv Inc, London, ON, Canada, London, ON, Canada, ⁷Janssen Research & Development, Cambridge, MA, USA, Cambridge, MA
Background/Purpose: Combination induction therapy with guselkumab (GUS), an interleukin (IL)-23p19 subunit antagonist, and golimumab (GOL), a tumor necrosis factor (TNFα) antagonist, induced higher rates of…
Abstract Number: 2103 • ACR Convergence 2024
Synovial Inflammation Is Increased in Females with Knee Osteoarthritis
Caryn Hale¹, Miguel Otero², Dongmei Sun³, Michael Parides⁴, Edward Dicarlo⁵, dana Orange⁶, Yiyuan Wu⁷, William Robinson⁸, Bella Mehta⁵, Solana Cushing⁴, Peter Sculco⁴, Tristan Maerz⁹, Anne-Marie Malfait¹⁰, Daniel Ramirez¹¹ and Aimee Colbath¹², ¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Hospital for Special Surgery, NYC, ³Hospital for Special Surgery, Birmingham, AL, ⁴Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Rockefeller University, New York, NY, ⁷Weill Cornell Medicine, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Rush University, New York, NY, ¹¹Hospital for Special Surgery, Cartago, Costa Rica, ¹²Cornell University College of Veterinary Medicine, New York, NY
Background/Purpose: Symptomatic knee osteoarthritis (OA) is more common in women than men. We sought to compare clinical and histological features and synovial gene expression between…
Abstract Number: 0711 • ACR Convergence 2024
Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Natania Field¹, Monica Yang², Niket Gupta¹, Maxwell Shramuk¹, Lutfiyya Muhammad¹, Vivien Goh¹, Monica Espinoza³, Yiwei Yuan³, Rezvan Parvizi³, Kathleen Aren⁴, Mary Carns⁴, Isaac Goldberg⁵, Lorinda Chung⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield³ and Monique Hinchcliff⁹, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²UCSF, San Francisco, CA, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Wayne State University School of Medicine, Detroit, MI, ⁶Stanford University, Woodside, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Yale School of Medicine, Westport, CT
Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
Abstract Number: 1458 • ACR Convergence 2024
Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients
Pauline KRUG¹, angela De Sousa Leite², Frédéric Lecouvet¹, Maria Simona stoenoiu¹ and Adrien Nzeusseu Toukap³, ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires St-Luc, Brussels, Belgium, ³Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogeneous disease. The response to therapy is variable among patients (ref.). Therefore, we need a tailored approach. Biologic…
Abstract Number: 2200 • ACR Convergence 2024
Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature
Rania Elbakri¹, Amanda Robinson², Anwesha Sanyal¹ and Kathryn Torok³, ¹University of Pittsburgh, pittsburgh, PA, ²University of Utah Health, Salt Lake City, UT, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare chronic autoimmune disorder characterized by skin thickening and multisystem organ involvement, leading to significant morbidity. The pathogenesis…
Abstract Number: 0759 • ACR Convergence 2024
Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media
Makoto Sugihara¹, Nobumasa Watanabe², Yuichiro Hara², Yasumasa Nishito³, Mai Kounoe⁴, Kazunari Sekiyama⁴, Eisuke Takamasu⁵, Naofumi Chinen⁶, Kota Shimada⁵ and Hideya Kawaji², ¹Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan, Higashimurayama-shi, Tokyo, Japan, ²Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ³Center for Basic Technology Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ⁴Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, ⁵Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, Fuchu-shi, Tokyo, Japan, ⁶Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tokyo, Japan, Tama-shi, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis characterized by inflammatory cell infiltration and destruction of the tunica media. In this study, we…
Abstract Number: 1507 • ACR Convergence 2024
To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Tokunaga³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Tokyo, ³Japanese Red Cross Okayama Hospital, Okayama
Background/Purpose: IFN signatures are known to play an important role in the pathogenesis of systemic autoimmune diseases such as SLE. Recently, therapeutic agents targeting IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].